{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:22:45Z","timestamp":1762341765880},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00108-021-01199-3","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T18:03:58Z","timestamp":1635444238000},"page":"1259-1268","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Was ist gesichert in der Therapie der autosomal-dominanten polyzystischen Nierenerkrankung?"],"prefix":"10.1007","volume":"62","author":[{"given":"Vera Christine","family":"Wulfmeyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"issue":"1","key":"1199_CR1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann\u00a0C, Guay-Woodford\u00a0LM, Harris\u00a0PC et al (2018) Polycystic kidney disease. Nat Rev Dis Primers 4(1):50","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1199_CR2","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven\u00a0EM, Kramer\u00a0A, Meijer\u00a0E et al (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 29(4):iv15\u201325","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1199_CR3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.1984.154","volume":"26","author":"DN Churchill","year":"1984","unstructured":"Churchill\u00a0DN, Bear\u00a0JC, Morgan\u00a0J et al (1984) Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26(2):190\u2013193","journal-title":"Kidney Int"},{"key":"1199_CR4","unstructured":"European Medicines Agency (2015) Public assessment report Jinarc. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002788\/WC500187923.pdf. Zugegriffen: 22. Juli 2021"},{"issue":"12","key":"1199_CR5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/archdischild-2015-310221","volume":"101","author":"M Marlais","year":"2016","unstructured":"Marlais\u00a0M, Cuthell\u00a0O, Langan\u00a0D et al (2016) Hypertension in autosomal dominant polycystic kidney disease: a\u00a0meta-analysis. Arch Dis Child 101(12):1142\u20131147","journal-title":"Arch Dis Child"},{"issue":"6","key":"1199_CR6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.11401017","volume":"13","author":"L Massella","year":"2018","unstructured":"Massella\u00a0L, Mekahli\u00a0D, Paripovic\u00a0D et al (2018) Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13(6):874\u2013883","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"1199_CR7","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier\u00a0RW, Abebe\u00a0KZ, Perrone\u00a0RD et\u00a0al (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N\u00a0Engl J Med 371(24):2255\u20132266","journal-title":"N Engl J Med"},{"issue":"11","key":"1199_CR8","first-page":"1857","volume":"32","author":"MV Irazabal","year":"2017","unstructured":"Irazabal\u00a0MV, Abebe\u00a0KZ, Bae\u00a0KT et al (2017) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 32(11):1857\u20131865","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1199_CR9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000046231","volume":"21","author":"T Ecder","year":"2001","unstructured":"Ecder\u00a0T, Edelstein\u00a0CL, Fick-Brosnahan\u00a0GM et al (2001) Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 21(2):98\u2013103","journal-title":"Am J Nephrol"},{"issue":"11","key":"1199_CR10","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","volume":"18","author":"MA van Dijk","year":"2003","unstructured":"van Dijk\u00a0MA, Breuning\u00a0MH, Duiser\u00a0R et\u00a0al (2003) No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18(11):2314\u20132320","journal-title":"Nephrol Dial Transplant"},{"issue":"24","key":"1199_CR11","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","volume":"371","author":"VE Torres","year":"2014","unstructured":"Torres\u00a0VE, Abebe\u00a0KZ, Chapman\u00a0AB et\u00a0al (2014) Angiotensin blockade in late autosomal dominant polycystic kidney disease. N\u00a0Engl J Med 371(24):2267\u20132276","journal-title":"N Engl J Med"},{"issue":"4","key":"1199_CR12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/qjmed\/hcz326","volume":"113","author":"R El-Damanawi","year":"2020","unstructured":"El-Damanawi\u00a0R, Lee\u00a0M, Harris\u00a0T et al (2020) High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a\u00a0randomized controlled feasibility trial. QJM 113(4):306","journal-title":"QJM"},{"issue":"6","key":"1199_CR13","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","volume":"4","author":"VE Torres","year":"2009","unstructured":"Torres\u00a0VE, Bankir\u00a0L, Grantham\u00a0JJ (2009) A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 4(6):1140\u20131150","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1199_CR14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","volume":"91","author":"VE Torres","year":"2017","unstructured":"Torres\u00a0VE, Abebe\u00a0KZ, Schrier\u00a0RW et\u00a0al (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91(2):493\u2013500","journal-title":"Kidney Int"},{"issue":"4","key":"1199_CR15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","volume":"98","author":"BJ Kramers","year":"2020","unstructured":"Kramers\u00a0BJ, Koorevaar\u00a0IW, Drenth\u00a0JPH et\u00a0al (2020) Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. Kidney Int 98(4):989\u2013998","journal-title":"Kidney Int"},{"issue":"1","key":"1199_CR16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12882-018-1182-0","volume":"19","author":"KA McKenzie","year":"2018","unstructured":"McKenzie\u00a0KA, El Ters\u00a0M, Torres\u00a0VE et\u00a0al (2018) Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a\u00a0retrospective analysis using the CRISP cohort. BMC Nephrol 19(1):378","journal-title":"BMC Nephrol"},{"issue":"2","key":"1199_CR17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","volume":"29","author":"KL Nowak","year":"2018","unstructured":"Nowak\u00a0KL, You\u00a0Z, Gitomer\u00a0B et\u00a0al (2018) Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J\u00a0Am Soc Nephrol 29(2):571\u2013578","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1199_CR18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","volume":"30","author":"JA Torres","year":"2019","unstructured":"Torres\u00a0JA, Kruger\u00a0SL, Broderick\u00a0C et\u00a0al (2019) Ketosis ameliorates renal cyst growth in polycystic kidney disease. Cell Metab 30(6):1007\u20131023.e5","journal-title":"Cell Metab"},{"issue":"1","key":"1199_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41581-019-0226-4","volume":"16","author":"EF Carney","year":"2020","unstructured":"Carney\u00a0EF (2020) Ketosis slows the progression of PKD. Nat Rev Nephrol 16(1):1","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"1199_CR20","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","volume":"9","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai\u00a0MA, George\u00a0DM, McFann\u00a0K et\u00a0al (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9(5):889\u2013896","journal-title":"Clin J Am Soc Nephrol"},{"key":"1199_CR21","volume-title":"Statin therapy in patients with early stage ADPKD","author":"ClinicalTrials.org","year":"2020","unstructured":"ClinicalTrials.org (2020) Statin therapy in patients with early stage ADPKD"},{"issue":"4","key":"1199_CR22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000502634","volume":"50","author":"VC Wulfmeyer","year":"2019","unstructured":"Wulfmeyer\u00a0VC, Auber\u00a0B, Haller\u00a0H et\u00a0al (2019) Comparison of different selection strategies for tolvaptan eligibility among autosomal dominant polycystic kidney disease patients. Am J Nephrol 50(4):281\u2013290","journal-title":"Am J Nephrol"},{"issue":"20","key":"1199_CR23","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham\u00a0JJ, Torres\u00a0VE, Chapman\u00a0AB et\u00a0al (2006) Volume progression in polycystic kidney disease. N\u00a0Engl J Med 354(20):2122\u20132130","journal-title":"N Engl J Med"},{"issue":"3","key":"1199_CR24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman\u00a0AB, Bost\u00a0JE, Torres\u00a0VE et\u00a0al (2012) Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7(3):479\u2013486","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1199_CR25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal\u00a0MV, Rangel\u00a0LJ, Bergstralh\u00a0EJ et\u00a0al (2015) Imaging classification of autosomal dominant polycystic kidney disease: a\u00a0simple model for selecting patients for clinical trials. J\u00a0Am Soc Nephrol 26(1):160\u2013172","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1199_CR26","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib\u00a0FT, Perrone\u00a0RD, Chapman\u00a0AB et\u00a0al (2018) A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J\u00a0Am Soc Nephrol 29(10):2458\u20132470","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1199_CR27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","volume":"2","author":"RD Perrone","year":"2017","unstructured":"Perrone\u00a0RD, Mouksassi\u00a0MS, Romero\u00a0K et al (2017) Total kidney volume is a\u00a0prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2(3):442\u2013450","journal-title":"Kidney Int Rep"},{"issue":"20","key":"1199_CR28","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres\u00a0VE, Chapman\u00a0AB, Devuyst\u00a0O et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N\u00a0Engl J Med 377(20):1930\u20131942","journal-title":"N Engl J Med"},{"issue":"25","key":"1199_CR29","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres\u00a0VE, Chapman\u00a0AB, Devuyst\u00a0O et\u00a0al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N\u00a0Engl J Med 367(25):2407\u20132418","journal-title":"N Engl J Med"},{"issue":"1","key":"1199_CR30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","volume":"88","author":"H Bhutani","year":"2015","unstructured":"Bhutani\u00a0H, Smith\u00a0V, Rahbari-Oskoui\u00a0F et al (2015) A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int 88(1):146\u2013151","journal-title":"Kidney Int"},{"issue":"3","key":"1199_CR31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort\u00a0RT, Arici\u00a0M, Benzing\u00a0T et al (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a\u00a0position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant 31(3):337\u2013348","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1199_CR32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall\u00a0E, Audrezet\u00a0MP, Rousseau\u00a0A et al (2016) The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J\u00a0Am Soc Nephrol 27(3):942\u2013951","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1199_CR33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","volume":"73","author":"BJ Kramers","year":"2019","unstructured":"Kramers\u00a0BJ, van Gastel\u00a0MDA, Boertien\u00a0WE et\u00a0al (2019) Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan. Am J Kidney Dis 73(3):354\u2013362","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1199_CR34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11255-020-02384-3","volume":"52","author":"G Cote","year":"2020","unstructured":"Cote\u00a0G, Asselin-Thompstone\u00a0L, Mac-Way\u00a0F et al (2020) Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention. Int Urol Nephrol 52(2):343\u2013349","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"1199_CR35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12882-018-0957-7","volume":"19","author":"BJ Kramers","year":"2018","unstructured":"Kramers\u00a0BJ, van Gastel\u00a0MDA, Meijer\u00a0E et\u00a0al (2018) Case report: a\u00a0thiazide diuretic to treat polyuria induced by tolvaptan. BMC Nephrol 19(1):157","journal-title":"BMC Nephrol"},{"issue":"1","key":"1199_CR36","doi-asserted-by":"crossref","first-page":"17666","DOI":"10.1038\/s41598-021-97113-w","volume":"11","author":"K Uchiyama","year":"2021","unstructured":"Uchiyama\u00a0K, Kitayama\u00a0C, Yanai\u00a0A et\u00a0al (2021) The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a\u00a0randomized crossover controlled trial. Sci Rep 11(1):17666","journal-title":"Sci Rep"},{"key":"1199_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa150","author":"BJ Kramers","year":"2020","unstructured":"Kramers\u00a0BJ, Koorevaar\u00a0IW, De Boer\u00a0R et\u00a0al (2020) Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa150","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1199_CR38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10157-020-02009-0","volume":"25","author":"S Horie","year":"2021","unstructured":"Horie\u00a0S, Muto\u00a0S, Kawano\u00a0H et\u00a0al (2021) Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol 25(5):467\u2013478","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1199_CR39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.15586\/jrenhep.2017.10","volume":"1","author":"M Salvadori","year":"2017","unstructured":"Salvadori\u00a0M, Tsalouchos\u00a0A (2017) Novel therapeutic strategies targeting molecular pathways of cystogenesis in autosomal polycystic kidney disease. J\u00a0Ren Hepatic Disord 1(1):35\u201349","journal-title":"J Ren Hepatic Disord"},{"key":"1199_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-021-01062-6","author":"I Capuano","year":"2021","unstructured":"Capuano\u00a0I, Buonanno\u00a0P, Riccio\u00a0E et\u00a0al (2021) Therapeutic advances in ADPKD: the future awaits. J\u00a0Nephrol. https:\/\/doi.org\/10.1007\/s40620-021-01062-6","journal-title":"J Nephrol"},{"issue":"9","key":"1199_CR41","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra\u00a0AL, Poster\u00a0D, Kistler\u00a0AD et\u00a0al (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N\u00a0Engl J Med 363(9):820\u2013829","journal-title":"N Engl J Med"},{"issue":"6","key":"1199_CR42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","volume":"21","author":"N Perico","year":"2010","unstructured":"Perico\u00a0N, Antiga\u00a0L, Caroli\u00a0A et\u00a0al (2010) Sirolimus therapy to halt the progression of ADPKD. J\u00a0Am Soc Nephrol 21(6):1031\u20131040","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1199_CR43","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz\u00a0G, Budde\u00a0K, Mannaa\u00a0M et\u00a0al (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N\u00a0Engl J Med 363(9):830\u2013840","journal-title":"N Engl J Med"},{"issue":"11","key":"1199_CR44","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","volume":"28","author":"V Tesar","year":"2017","unstructured":"Tesar\u00a0V, Ciechanowski\u00a0K, Pei\u00a0Y et\u00a0al (2017) Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J\u00a0Am Soc Nephrol 28(11):3404\u20133413","journal-title":"J Am Soc Nephrol"},{"key":"1199_CR45","unstructured":"ClinicalTrials.org (2018) A medical research study designed to determine if venglustat can be a\u00a0future treatment for ADPKD patients (STAGED-PKD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03523728. Zugegriffen: 6. Sept. 2021"},{"key":"1199_CR46","doi-asserted-by":"crossref","first-page":"109703","DOI":"10.1016\/j.cellsig.2020.109703","volume":"73","author":"F Jouret","year":"2020","unstructured":"Jouret\u00a0F, Devuyst\u00a0O (2020) Targeting chloride transport in autosomal dominant polycystic kidney disease. Cell Signal 73:109703","journal-title":"Cell Signal"},{"issue":"4","key":"1199_CR47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","volume":"365","author":"PE Pergola","year":"2011","unstructured":"Pergola\u00a0PE, Raskin\u00a0P, Toto\u00a0RD et\u00a0al (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N\u00a0Engl J Med 365(4):327\u2013336","journal-title":"N Engl J Med"},{"key":"1199_CR48","doi-asserted-by":"crossref","first-page":"iv142","DOI":"10.1093\/ndt\/gfu073","volume":"4","author":"NF Casteleijn","year":"2014","unstructured":"Casteleijn\u00a0NF, Visser\u00a0FW, Drenth\u00a0JP et al (2014) A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 4:iv142\u2013153","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1199_CR49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ndt\/gfu227","volume":"30","author":"MA Lantinga","year":"2015","unstructured":"Lantinga\u00a0MA, Drenth\u00a0JP, Gevers\u00a0TJ (2015) Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant 30(5):744\u2013751","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1199_CR50","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1093\/ndt\/gfs352","volume":"27","author":"F Jouret","year":"2012","unstructured":"Jouret\u00a0F, Lhommel\u00a0R, Devuyst\u00a0O et\u00a0al (2012) Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transplant 27(10):3746\u20133751","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1199_CR51","doi-asserted-by":"crossref","first-page":"e0161277","DOI":"10.1371\/journal.pone.0161277","volume":"11","author":"M Neuville","year":"2016","unstructured":"Neuville\u00a0M, Hustinx\u00a0R, Jacques\u00a0J et\u00a0al (2016) Diagnostic algorithm in the management of acute febrile abdomen in patients with autosomal dominant polycystic kidney disease. PLoS ONE 11(8):e161277","journal-title":"PLoS ONE"},{"issue":"1","key":"1199_CR52","first-page":"144","volume":"32","author":"MA Lantinga","year":"2017","unstructured":"Lantinga\u00a0MA, Casteleijn\u00a0NF, Geudens\u00a0A et\u00a0al (2017) Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a\u00a0systematic review. Nephrol Dial Transplant 32(1):144\u2013150","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1199_CR53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman\u00a0AB, Devuyst\u00a0O, Eckardt\u00a0KU et al (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a\u00a0kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88(1):17\u201327","journal-title":"Kidney Int"},{"issue":"1","key":"1199_CR54","doi-asserted-by":"crossref","first-page":"19460","DOI":"10.1038\/s41598-020-76520-5","volume":"10","author":"IC Kuo","year":"2020","unstructured":"Kuo\u00a0IC, Lee\u00a0JJ, Hwang\u00a0DY et\u00a0al (2020) Pyuria, urinary tract infection and renal outcome in patients with chronic kidney disease stage 3\u20135. Sci Rep 10(1):19460","journal-title":"Sci Rep"},{"issue":"1","key":"1199_CR55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jamcollsurg.2015.12.051","volume":"223","author":"FT Chebib","year":"2016","unstructured":"Chebib\u00a0FT, Harmon\u00a0A, Irazabal Mira\u00a0MV et\u00a0al (2016) Outcomes and durability of hepatic reduction after combined partial hepatectomy and cyst fenestration for massive polycystic liver disease. J\u00a0Am Coll Surg 223(1):118\u2013126.e1","journal-title":"J Am Coll Surg"},{"issue":"6","key":"1199_CR56","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.semnephrol.2015.10.012","volume":"35","author":"A Mallett","year":"2015","unstructured":"Mallett\u00a0A, Patel\u00a0M, Tunnicliffe\u00a0DJ et al (2015) KHA-CARI autosomal dominant polycystic kidney disease guideline: management of renal stone disease. Semin Nephrol 35(6):603\u2013606.e3","journal-title":"Semin Nephrol"},{"issue":"5","key":"1199_CR57","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","volume":"67","author":"FT Chebib","year":"2016","unstructured":"Chebib\u00a0FT, Torres\u00a0VE (2016) Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis 67(5):792\u2013810","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1199_CR58","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1681\/ASN.V491661","volume":"4","author":"DS Keith","year":"1994","unstructured":"Keith\u00a0DS, Torres\u00a0VE, King\u00a0BF et\u00a0al (1994) Renal cell carcinoma in autosomal dominant polycystic kidney disease. J\u00a0Am Soc Nephrol 4(9):1661\u20131669","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1199_CR59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12957-016-0916-3","volume":"14","author":"L Xu","year":"2016","unstructured":"Xu\u00a0L, Rong\u00a0Y, Wang\u00a0W et al (2016) Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease. World J Surg Oncol 14(1):193","journal-title":"World J Surg Oncol"},{"issue":"2","key":"1199_CR60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/ckj\/sft171","volume":"7","author":"C Courivaud","year":"2014","unstructured":"Courivaud\u00a0C, Roubiou\u00a0C, Delabrousse\u00a0E et\u00a0al (2014) Polycystic kidney size and outcomes on peritoneal dialysis: comparison with haemodialysis. Clin Kidney\u00a0J 7(2):138\u2013143","journal-title":"Clin Kidney J"},{"issue":"2","key":"1199_CR61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfs118","volume":"28","author":"HP Neeff","year":"2013","unstructured":"Neeff\u00a0HP, Pisarski\u00a0P, Tittelbach-Helmrich\u00a0D et al (2013) One hundred consecutive kidney transplantations with simultaneous ipsilateral nephrectomy in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 28(2):466\u2013471","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1199_CR62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfv227","volume":"31","author":"Y Jung","year":"2016","unstructured":"Jung\u00a0Y, Irazabal\u00a0MV, Chebib\u00a0FT et\u00a0al (2016) Volume regression of native polycystic kidneys after renal transplantation. Nephrol Dial Transplant 31(1):73\u201379","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1199_CR63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ndt\/gft437","volume":"29","author":"RL Luciano","year":"2014","unstructured":"Luciano\u00a0RL, Dahl\u00a0NK (2014) Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol Dial Transplant 29(2):247\u2013254","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1199_CR64","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/cpt.1553","volume":"106","author":"RMM van Aerts","year":"2019","unstructured":"van Aerts\u00a0RMM, Bernts\u00a0LHP, Gevers\u00a0TJG et al (2019) Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in premenopausal patients. Clin Pharmacol Ther 106(6):1338\u20131345","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1199_CR65","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/gut.2008.155721","volume":"57","author":"L van Keimpema","year":"2008","unstructured":"van Keimpema\u00a0L, de Man\u00a0RA, Drenth\u00a0JP (2008) Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 57(9):1338\u20131339","journal-title":"Gut"},{"issue":"5","key":"1199_CR66","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","volume":"5","author":"A Caroli","year":"2010","unstructured":"Caroli\u00a0A, Antiga\u00a0L, Cafaro\u00a0M et\u00a0al (2010) Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 5(5):783\u2013789","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1199_CR67","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","volume":"90","author":"MC Hogan","year":"2015","unstructured":"Hogan\u00a0MC, Masyuk\u00a0T, Bergstralh\u00a0E et al (2015) Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease. Mayo Clin Proc 90(8):1030\u20131037","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1199_CR68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2013.04.055","volume":"145","author":"TJ Gevers","year":"2013","unstructured":"Gevers\u00a0TJ, Inthout\u00a0J, Caroli\u00a0A et\u00a0al (2013) Young women with polycystic liver disease respond best to somatostatin analogues: a\u00a0pooled analysis of individual patient data. Gastroenterology 145(2):357\u2013365.e1\u20132","journal-title":"Gastroenterology"},{"issue":"1","key":"1199_CR69","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1681\/ASN.V131269","volume":"13","author":"Y Pirson","year":"2002","unstructured":"Pirson\u00a0Y, Chauveau\u00a0D, Torres\u00a0V (2002) Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J\u00a0Am Soc Nephrol 13(1):269\u2013276","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1199_CR70","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1017\/S0317167100017984","volume":"38","author":"RD Brown","year":"2011","unstructured":"Brown\u00a0RD, Torner\u00a0J (2011) Unruptured intracranial aneurysms: some questions answered, many questions remain. Re: Pelz D. CURES and the dilemma of unruptured intracranial aneurysms. Can J Neuro Sci. 2011 Mar;38(2):191\u20132. Can J Neurol Sci 38(5):785\u2013787","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"1199_CR71","doi-asserted-by":"crossref","first-page":"e0153176","DOI":"10.1371\/journal.pone.0153176","volume":"11","author":"A Flahault","year":"2016","unstructured":"Flahault\u00a0A, Trystram\u00a0D, Fouchard\u00a0M et\u00a0al (2016) Screening for unruptured Intracranial aneurysms in autosomal dominant polycystic kidney disease: a survey of 420 nephrologists. PLoS ONE 11(4):e153176","journal-title":"PLoS ONE"},{"issue":"8","key":"1199_CR72","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.2215\/CJN.02100219","volume":"14","author":"A Flahault","year":"2019","unstructured":"Flahault\u00a0A, Joly\u00a0D (2019) Screening for Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 14(8):1242\u20131244","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1199_CR73","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.ki.5002488","volume":"72","author":"T Ring","year":"2007","unstructured":"Ring\u00a0T, Spiegelhalter\u00a0D (2007) Risk of intracranial aneurysm bleeding in autosomal-dominant polycystic kidney disease. Kidney Int 72(11):1400\u20131402","journal-title":"Kidney Int"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01199-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T12:07:39Z","timestamp":1638965259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01199-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01199-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"1 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"V.C.\u00a0Wulfmeyer gibt an, dass kein Interessenkonflikt besteht. R.\u00a0Schmitt hat in den letzten 3\u00a0Jahren Honorare f\u00fcr Vortr\u00e4ge von Otsuka und FMC erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}